US EditionEli Lilly launches its blockbuster weight loss drug Mounjaro in India
- Eli Lilly and Company announced the launch of Mounjaro in India after receiving marketing authorization from the Central Drugs Standard Control Organization .
- Mounjaro is a first-of-its-kind treatment for obesity and type 2 diabetes that activates both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 hormone receptors.
- The drug aims to aid in chronic weight management for adults with specific body mass index criteria and improve glycemic control in those with type 2 diabetes mellitus.
24 Articles
24 Articles
Milind Deora slams weight-loss drug Mounjaro's launch, calls for higher sugar taxes
Rajya Sabha member Milind Deora has criticised the launch of Mounjaro in India. The weight-loss drug, developed by US-based Eli Lilly, is a weekly injectable medicine that costs Rs 3,500 for the 2.5 mg vial.
Eli Lilly's weight loss drug Mounjaro launched in India; check prices, how it works
Eli Lilly and Company launched its weight loss drug Mounjaro in India on Thursday after obtaining approval from the Central Drugs Standard Control Organisation (CDSCO). This is a drug which activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors which eventually help with obesity, overweight and type 2 diabetes. Price of Mounjaro in India According to the company, the injection is s…
Blockbuster weight-loss drug Mounjaro comes to India: How does it work?
Mounjaro, now launched in India, is the brand name of the drug called tirzepatide. Like its competitors Ozempic and Wegovy (brand names for the drug semaglutide), it is an injectable that needs to be used once a week. Experts say Mounjaro, which works by binding and activating two receptors – glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) – has shown incredible results when paired with diet and exercise w…
Coverage Details
Bias Distribution
- 56% of the sources lean Right
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
